Click Here to
News, Updates,
& More
Stay Up
to Date

JHOP - March 2019 Vol 9, No 1

Front-line ibrutinib therapy results in a lower rate of disease progression or death than the current standard-of-care chemoimmunotherapy with bendamustine and rituximab in older patients with chronic lymphocytic leukemia (CLL). Adding rituximab to ibrutinib did not improve outcomes compared with ibrutinib alone, reported Jennifer A. Woyach, MD, Associate Professor, Ohio State University Comprehensive Cancer Center, Columbus, at ASH 2018.
Page 2 of 2
Results 11 - 11 of 11